Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India

Eli Lilly & Company has experienced a significant decline in its market share within India's GLP-1 receptor agonist market for weight-loss and diabetes drugs, while its main competitor, Novo Nordisk, has managed to maintain its position, according to recent market analysis. This shift occurred in India over recent months as a wave of low-cost generic versions of semaglutide flooded the market. Novo Nordisk's resilience is attributed to aggressive price reductions on its branded drugs Ozempic and Wegovy, a defensive strategy to counter the generic competition that Eli Lilly did not match with its products, Mounjaro and Zepbound. The Indian pharmaceutical market has become a key battleground for affordable versions of blockbuster GLP-1 drugs. The influx of generic semaglutide, which mimics the active ingredient in Novo's Ozempic, has provided a substantially cheaper alternative for patients, putting immense pricing pressure on the original innovators. While both multinational firms faced this challenge, their strategic responses diverged sharply. Novo Nordisk opted for a preemptive and deep price-cutting campaign for its injectable therapies, effectively narrowing the price gap with generics and convincing a portion of the market to stay with the trusted, branded product. In contrast, Eli Lilly, which markets the tirzepatide-based drugs Mounjaro and Zepbound, did not implement similarly aggressive pricing measures. Consequently, its products became relatively more expensive compared to both the new generics and Novo's discounted offerings, leading to a measurable erosion of its market share. This dynamic highlights the critical importance of pricing strategy in emerging markets like India, where cost sensitivity is extremely high. The situation also underscores the rapid adaptability of the Indian generic pharmaceutical industry, which can quickly replicate and commercialize complex biologic and peptide drugs, fundamentally altering competitive landscapes.